- Home
- EVAX vs MMA Comparison
EVAX vs MMA Comparison
Compare EVAX & MMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- MMA
- Stock Information
- Founded
- EVAX 2008
- MMA 2013
- Country
- EVAX Denmark
- MMA Australia
- Employees
- EVAX N/A
- MMA N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- MMA
- Sector
- EVAX Health Care
- MMA
- Exchange
- EVAX Nasdaq
- MMA Nasdaq
- Market Cap
- EVAX 16.3M
- MMA 15.9M
- IPO Year
- EVAX 2021
- MMA 2024
- Fundamental
- Price
- EVAX $1.64
- MMA $0.77
- Analyst Decision
- EVAX Strong Buy
- MMA
- Analyst Count
- EVAX 2
- MMA 0
- Target Price
- EVAX $10.00
- MMA N/A
- AVG Volume (30 Days)
- EVAX 64.1K
- MMA 72.8K
- Earning Date
- EVAX 05-27-2025
- MMA 01-21-2025
- Dividend Yield
- EVAX N/A
- MMA N/A
- EPS Growth
- EVAX N/A
- MMA N/A
- EPS
- EVAX N/A
- MMA N/A
- Revenue
- EVAX $3,344,000.00
- MMA $375,175.00
- Revenue This Year
- EVAX $102.45
- MMA N/A
- Revenue Next Year
- EVAX $100.30
- MMA N/A
- P/E Ratio
- EVAX N/A
- MMA N/A
- Revenue Growth
- EVAX 4480.82
- MMA 45.19
- 52 Week Low
- EVAX $1.20
- MMA $0.60
- 52 Week High
- EVAX $20.81
- MMA $5.00
- Technical
- Relative Strength Index (RSI)
- EVAX 55.67
- MMA N/A
- Support Level
- EVAX $1.42
- MMA N/A
- Resistance Level
- EVAX $1.62
- MMA N/A
- Average True Range (ATR)
- EVAX 0.11
- MMA 0.00
- MACD
- EVAX 0.03
- MMA 0.00
- Stochastic Oscillator
- EVAX 62.86
- MMA 0.00
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About MMA Alta Global Group Limited
Mixed Martial Arts Group Ltd formerly Alta Global Group Ltd is a technology company engaged in the provision and administration of mixed martial arts training programs, and gym programs. It provides subscription-based products and services, offering both B2B SaaS solutions and B2C products and programs, covering online engagement, online content, and immersive in-gym experiences. The company's business units are; Trainalta.com; Mixed Martial Arts.com; and Hype.Co, Mobile Marketing solution. Its Alta Platform serves as a comprehensive solution for martial arts and combat sports, offering a blend of four core products: the Warrior Training Program, UFC Fight Fit Program, Alta Academy, and the Alta Community.